Key Points
- Insider Rainer Erdtmann purchased 30,000 shares of Biomea Fusion on Dec. 11 at $1.43 per share (≈$42,900), increasing his direct ownership to 723,027 shares — a 4.33% boost.
- Biomea Fusion is a small-cap clinical-stage biotech (market cap ~$94.7M) trading around $1.34, reporting a quarterly EPS of -$0.27 (miss) and analysts forecast roughly -3.93 EPS for the year, with a one-year price range of $0.87–$6.06.
- Institutional ownership is very high at 96.72%, and analysts' consensus is a “Moderate Buy” with an average target price of $8.88.
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) insider Rainer Erdtmann bought 30,000 shares of the company's stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $1.43 per share, for a total transaction of $42,900.00. Following the acquisition, the insider directly owned 723,027 shares of the company's stock, valued at $1,033,928.61. The trade was a 4.33% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Biomea Fusion Price Performance
Shares of NASDAQ BMEA opened at $1.34 on Tuesday. The company has a market capitalization of $94.74 million, a price-to-earnings ratio of -0.56 and a beta of -0.14. The business has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.73. Biomea Fusion, Inc. has a 1 year low of $0.87 and a 1 year high of $6.06.
Biomea Fusion (NASDAQ:BMEA - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01). As a group, equities research analysts expect that Biomea Fusion, Inc. will post -3.93 earnings per share for the current year.
Institutional Investors Weigh In On Biomea Fusion
Institutional investors and hedge funds have recently made changes to their positions in the business. Scientech Research LLC acquired a new stake in shares of Biomea Fusion during the third quarter worth about $25,000. Engineers Gate Manager LP acquired a new stake in Biomea Fusion during the 2nd quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Biomea Fusion during the 3rd quarter worth approximately $32,000. Virtu Financial LLC purchased a new position in shares of Biomea Fusion in the 3rd quarter valued at approximately $39,000. Finally, Marex Group plc acquired a new position in shares of Biomea Fusion in the second quarter valued at approximately $81,000. 96.72% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have commented on BMEA. Weiss Ratings reiterated a "sell (e+)" rating on shares of Biomea Fusion in a research note on Wednesday, October 8th. Jefferies Financial Group began coverage on shares of Biomea Fusion in a research note on Thursday, August 28th. They set a "buy" rating and a $5.00 price target on the stock. Citigroup decreased their price objective on shares of Biomea Fusion from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Monday, November 10th. Finally, D. Boral Capital cut their target price on Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.88.
Get Our Latest Stock Report on Biomea Fusion
About Biomea Fusion
(
Get Free Report)
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
